微信公众号
证券之星APP
| 报告期 | 销售毛利率 | 同比 | 环比 | 行业排名 | 行业均值 | 行业龙头股 | 龙头股该指标值 | 查看 |
|---|---|---|---|---|---|---|---|---|
| 2026-03-31 | 45.83% | -1.19% | -2.24% | 84/157 | 50.55% | 泽璟制药 | 94.64% | 行业排名> |
| 2025-12-31 | 46.88% | -1.14% | -1.97% | 81/157 | 50.61% | 海创药业 | 99.82% | 行业排名> |
| 2025-09-30 | 47.82% | 0.36% | -1.55% | 80/157 | -2.2% | 海创药业 | 98.62% | 行业排名> |
| 2025-06-30 | 48.57% | 1.69% | 4.72% | 76/157 | 14.83% | 海创药业 | 99.57% | 行业排名> |
| 2025-03-31 | 46.39% | -2.07% | -2.18% | 77/157 | 31.96% | 海创药业 | 99.52% | 行业排名> |
| 2024-12-31 | 47.42% | -0.88% | -0.48% | 85/157 | 51.88% | 艾力斯 | 96.74% | 行业排名> |
| 2024-09-30 | 47.65% | -5.83% | -0.25% | 82/157 | 22.51% | 首药控股 | 98.96% | 行业排名> |
| 2024-06-30 | 47.77% | -5.33% | 0.85% | 82/157 | 33.12% | 迪哲医药 | 97.73% | 行业排名> |
| 2024-03-31 | 47.37% | -2.89% | -0.99% | 81/157 | 51.76% | 百利天恒 | 97.99% | 行业排名> |
| 2023-12-31 | 47.84% | -1.63% | -5.45% | 82/157 | 51.61% | 百利天恒 | 98.92% | 行业排名> |
| 2023-09-30 | 50.6% | -1.19% | 0.28% | 75/157 | 32.47% | 迈威生物 | 98.93% | 行业排名> |
| 2023-06-30 | 50.46% | -1.43% | 3.45% | 77/157 | 38.42% | 迈威生物 | 99.59% | 行业排名> |
| 2023-03-31 | 48.78% | -7.64% | 0.29% | 79/157 | 52.97% | 迈威生物 | 99.8% | 行业排名> |
| 2022-12-31 | 48.63% | 17.28% | -5.03% | 86/157 | 53.83% | 迈威生物 | 99.46% | 行业排名> |
| 2022-09-30 | 51.21% | 26.38% | 0.03% | 75/157 | 5.64% | 迈威生物 | 99.75% | 行业排名> |
| 2022-06-30 | 51.19% | 27.94% | -3.07% | 80/157 | 20.99% | 迈威生物 | 99.67% | 行业排名> |
| 2022-03-31 | 52.81% | 32.42% | 27.36% | 74/157 | 54.39% | 迈威生物 | 99.44% | 行业排名> |
| 2021-12-31 | 41.47% | -10.77% | 2.34% | 95/157 | 55.2% | 迈威生物 | 98.57% | 行业排名> |
| 2021-09-30 | 40.52% | -17.8% | 1.26% | 89/157 | 46.77% | 首药控股 | 99.93% | 行业排名> |
| 2021-06-30 | 40.01% | -24.45% | 0.33% | 99/157 | 47.23% | 艾力斯 | 99.41% | 行业排名> |
| 2021-03-31 | 39.88% | -28.34% | -14.19% | 84/157 | 54.13% | 艾力斯 | 98.7% | 行业排名> |
| 2020-12-31 | 46.48% | 0.75% | -5.72% | 87/157 | -148.64% | 艾力斯 | 99.4% | 行业排名> |
| 2020-09-30 | 49.29% | 11.02% | -6.93% | 69/157 | 56.43% | 首药控股 | 99.94% | 行业排名> |
| 2020-06-30 | 52.96% | 21.49% | -4.83% | 66/157 | 54.17% | 泽璟制药 | 99.96% | 行业排名> |
| 2020-03-31 | 55.65% | 32.44% | 20.64% | 50/157 | 55.17% | 微芯生物 | 95.14% | 行业排名> |
| 2019-12-31 | 46.13% | 4.66% | 3.9% | 86/157 | -1242.15% | 多瑞医药 | 95.59% | 行业排名> |
| 2019-09-30 | 44.4% | -1.95% | 1.85% | 69/157 | 55.23% | 微芯生物 | 95.81% | 行业排名> |
| 2019-06-30 | 43.59% | -10.17% | 3.74% | 74/157 | 55.21% | 微芯生物 | 96.09% | 行业排名> |
| 2019-03-31 | 42.02% | -25.67% | -4.67% | 70/157 | 51.07% | 微芯生物 | 96.11% | 行业排名> |
| 2018-12-31 | 44.08% | -22.99% | -2.66% | 84/157 | -211.97% | 微芯生物 | 95.5% | 行业排名> |
| 2018-09-30 | 45.28% | -19.92% | -6.69% | 62/157 | 54.14% | 微芯生物 | 96.27% | 行业排名> |
| 2018-06-30 | 48.53% | -9.45% | -14.16% | 58/157 | 53.53% | 贝达药业 | 95.47% | 行业排名> |
| 2018-03-31 | 56.53% | 1.04% | -1.23% | 46/157 | 54.16% | 贝达药业 | 95.51% | 行业排名> |
| 2017-12-31 | 57.23% | 13.22% | 1.21% | 51/157 | 52.55% | 贝达药业 | 95.54% | 行业排名> |
| 2017-09-30 | 56.55% | 16.82% | 5.51% | 34/157 | 49.09% | 贝达药业 | 95.74% | 行业排名> |
| 2017-06-30 | 53.59% | 11.11% | -4.22% | 39/157 | 47.91% | 退市金泰 | 96.19% | 行业排名> |
| 2017-03-31 | 55.95% | 27.29% | 10.69% | 29/157 | 46.94% | 贝达药业 | 95.81% | 行业排名> |
| 2016-12-31 | 50.55% | 25.15% | 4.43% | 49/157 | 48.46% | 退市金泰 | 95.93% | 行业排名> |
| 2016-09-30 | 48.4% | 20.87% | 0.36% | 32/157 | 46.19% | 贝达药业 | 95.58% | 行业排名> |
| 2016-06-30 | 48.23% | 21.53% | 9.73% | 37/157 | 46.26% | 贝达药业 | 95.89% | 行业排名> |
| 2016-03-31 | 43.96% | 7.36% | 8.82% | 36/157 | 43.86% | 微芯生物 | 97.46% | 行业排名> |